Reprogramming of Osimertinib-Resistant EGFR-mutant NSCLC: The Pyruvate-Acetaldehyde-Acetate Pathway As a Key Driver of ResistanceGiorgia Maroni, Elena Levantini, Eva Cabrera San Millán et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Dual actionability of BMI1 activation and mitotic vulnerability defines adaptive Osimertinib resistance in EGFR-mutant NSCLCPaolo Armanetti, Giorgia Maroni, Nicola Losito et al.|Cell Death and Disease|2026Cited by 1
The two sides of resistance: aggressiveness and mitotic instability as the Achilles’ heel of Osimertinib-resistant NSCLCPaolo Armanetti, Giorgia Maroni, Eva Cabrera San Millán et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
Deciphering the Role of Acetate in Metabolic Adaptation and Osimertinib Resistance in Non-Small Cell Lung CancerGiorgia Maroni, Emilia Bramanti, Eva Cabrera San Millán et al.|ArXiv.org|2025Cited by 0
Activation of a pyruvate-acetaldehyde-acetate metabolic shunt supports redox homeostasis in osimertinib-resistant EGFR-mutant non-small cell lung cancerGiorgia Maroni, Emilia Bramanti, Eva Cabrera San Millán et al.|Advances in Redox Research|2026Cited by 0